Search research articles
Contact Us
Filters
Showing results (81-90 of 112) with videos related to
Page
of 12
Sort By:
Blood
|
February 27, 2019
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet
Miguel A Sanz, Pierre Fenaux, Martin S Tallman, et al.
Haematologica
|
December 21, 2014
Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia
Eolia Brissot, Myriam Labopin, Marielle M Beckers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2024
Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial
Nigel H Russell, Abin Thomas, Robert K Hills, et al.
Blood
|
August 6, 2025
Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML
Jad Othman, Nicola Potter, Sylvie D Freeman, et al.
Blood Advances
|
May 12, 2023
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial
Jad Othman, Charlotte Wilhelm-Benartzi, Richard Dillon, et al.
Blood
|
August 18, 2023
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial
Sylvie D Freeman, Abin Thomas, Ian Thomas, et al.
Blood Advances
|
September 23, 2021
Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia
Ing S Tiong, Richard Dillon, Adam Ivey, et al.
The Lancet. Oncology
|
December 19, 2018
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
Graham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
The Lancet. Haematology
|
October 19, 2019
Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
Graham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
February 26, 2018
Cord Blood Unit Dominance Analysis and Effect of the Winning Unit on Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf of Eurocord, the Cord Blood Committee of Cellular Therapy, Immunobiology Working Party, and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Karina Tozatto-Maio, Federica Giannotti, Myriam Labopin, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 112) with videos related to
Sort By:
Page
of 12
Blood
|
February 27, 2019
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet
Miguel A Sanz, Pierre Fenaux, Martin S Tallman, et al.
Haematologica
|
December 21, 2014
Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia
Eolia Brissot, Myriam Labopin, Marielle M Beckers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2024
Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial
Nigel H Russell, Abin Thomas, Robert K Hills, et al.
Blood
|
August 6, 2025
Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML
Jad Othman, Nicola Potter, Sylvie D Freeman, et al.
Blood Advances
|
May 12, 2023
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial
Jad Othman, Charlotte Wilhelm-Benartzi, Richard Dillon, et al.
Blood
|
August 18, 2023
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial
Sylvie D Freeman, Abin Thomas, Ian Thomas, et al.
Blood Advances
|
September 23, 2021
Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia
Ing S Tiong, Richard Dillon, Adam Ivey, et al.
The Lancet. Oncology
|
December 19, 2018
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
Graham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
The Lancet. Haematology
|
October 19, 2019
Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
Graham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
February 26, 2018
Cord Blood Unit Dominance Analysis and Effect of the Winning Unit on Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf of Eurocord, the Cord Blood Committee of Cellular Therapy, Immunobiology Working Party, and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Karina Tozatto-Maio, Federica Giannotti, Myriam Labopin, et al.
Page
of 12